首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >A Stopped Pilot Study of the ProGlide Closure Device After Transbrachial Endovascular Interventions
【24h】

A Stopped Pilot Study of the ProGlide Closure Device After Transbrachial Endovascular Interventions

机译:贯穿渗透压血管内干预后的普形葡萄酒闭合装置的停止试验研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate the feasibility and safety of the suture-mediated ProGlide device in closure of the brachial artery after endovascular interventions. Materials and Methods: From 2016 to 2017, a pilot study was performed using the ProGlide to achieve hemostasis after percutaneous access of distal brachial arteries >4 mm in diameter. In an interim analysis, the results were compared to a matched control group taken from a 60-patient historical cohort who underwent brachial artery access and manual compression to achieve hemostasis between 2014 and 2017. The primary outcome was access-related reintervention and the secondary outcome was the incidence of access-site complications. Results: Seven patients (mean age 67.9 years; 6 men) were enrolled in the study before it was stopped in 2017. Four patients experienced 6 access-site complications (neuropathy, hematoma, occlusion, and pseudoaneurysm). These resulted in 3 access-related reinterventions: surgical evacuation of a hematoma, thrombectomy of the occluded brachial artery, and surgical repair of the pseudoaneurysm. In the interim comparison to the 19 matched patients (mean age 61.9 years; 6 men), the ProGlide group had proportionally more patients experiencing access-related complications (57% vs 16% for manual compression, p=0.035) and resultant reinterventions (43% vs 11%, p=0.064). Based on this data the trial was stopped. Conclusion: Considering this experience, it is not advisable to use the ProGlide in transbrachial endovascular interventions due to the high incidence of complications and access-related reinterventions.
机译:目的:评估血管外干预后骨折介导的普拉克里替代装置在腹血管干预后肱动脉闭合的可行性和安全性。材料和方法:从2016到2017年开始,使用普罗酮进行试验研究,以在远端肱动脉的远端肱动脉的经皮后进行止血,以实现止血剂>直径4mm。在临时分析中,将结果与来自60岁患者历史群组中的匹配对照组进行比较,曾在2014年和2017年之间进行肱动脉接入和手动压缩以实现止血。主要结果是与获取相关的重新入住和次要结果是访问现场并发症的发生率。结果:7名患者(平均年龄为67.9岁; 6名男子)在2017年停止之前注册了这项研究。四名患者经历了6名接入站点并发症(神经病变,血肿,闭塞和伪肿瘤)。这些导致3个接入相关的重新发明内:血肿的外科疏散,闭塞肱动脉的血栓切除,以及伪肿瘤的手术修复。在与19名匹配患者的临时比较(平均年龄61.9岁; 6名男性)中,Proglide组大幅增加了患者与获取相关的并发症的患者(57%对16%的手动压缩,P = 0.035)和合成的重新融合(43 %与11%,p = 0.064)。基于此数据,试验已停止。结论:考虑到这种经验,由于复杂的发病率和与获取相关的重新融合,不建议使用渗透压血管内干预中的普形曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号